Actively Recruiting
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
Led by Sanofi · Updated on 2025-12-22
350
Participants Needed
18
Research Sites
208 weeks
Total Duration
On this page
Sponsors
S
Sanofi
Lead Sponsor
R
Regeneron Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.
CONDITIONS
Official Title
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to sign informed consent for use of pseudonymized clinical data
- Adults aged 18 years or older
- Diagnosed with uncontrolled COPD despite treatment with LAMA/LABA/ICS (or LAMA/LABA if ICS not appropriate) and have elevated blood eosinophils
- Newly started on Dupilumab treatment as indicated in the approved product guidelines, independent of study participation
You will not qualify if you...
- Not eligible for Dupilumab treatment according to approved guidelines
- Participation in any interventional or observational study currently or within 12 months before enrollment that may affect study assessments
- Any acute or chronic condition that may limit ability to complete questionnaires or participate or affect study results as judged by the doctor
- Hospitalized due to COPD exacerbation within 4 weeks prior to enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Investigational Site Number: DE18
Auerbach, Germany, 08209
Actively Recruiting
2
Investigational Site Number: DE21
Augsburg, Germany, 86152
Actively Recruiting
3
Investigational Site Number: DE13
Bad Homburg, Germany, 61350
Actively Recruiting
4
Investigational Site Number: DE19
Berlin, Germany, 10717
Actively Recruiting
5
Investigational Site Number: DE02
Berlin, Germany, 14163
Actively Recruiting
6
Investigational Site Number: DE29
Burgwedel, Germany, 30938
Actively Recruiting
7
Investigational Site Number: DE01
Darmstadt, Germany, 64283
Actively Recruiting
8
Investigational Site Number: DE09
Erkelenz, Germany, 41812
Actively Recruiting
9
Investigational Site Number: DE06
Flensburg, Germany, 24937
Actively Recruiting
10
Investigational Site Number: DE08
Fürstenwalde, Germany, 15517
Actively Recruiting
11
Investigational Site Number: DE03
Hamburg, Germany, 20354
Actively Recruiting
12
Investigational Site Number: DE04
Hamburg, Germany, 22459
Actively Recruiting
13
Investigational Site Number: DE07
Hohenstein-Ernstthal, Germany, 09337
Actively Recruiting
14
Investigational Site Number: DE10
Itzehoe, Germany, 25524
Actively Recruiting
15
Investigational Site Number: DE24
Kaiserslauten, Germany, 67655
Actively Recruiting
16
Investigational Site Number: DE25
Lüneburg, Germany, 21339
Actively Recruiting
17
Investigational Site Number: DE20
Marburg, Germany, 35037
Actively Recruiting
18
Investigational Site Number: DE14
Markkleeberg, Germany, 04416
Actively Recruiting
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here